Drug intelligence / Profile preview

DM-71

Development stage: Unknown
Lead developer: DiaMedica Therapeutics
Modality: Small Molecules

Overview

**DM-71** is a novel investigational therapeutic agent developed by DiaMedica Inc. for the treatment of **type 2 diabetes**. In its first Phase II clinical trial, DM-71 demonstrated statistically significant reductions in **HbA1c**, **fructosamine**, and **body weight**, accompanied by an excellent safety profile in human patients[1][5]. The company has received FDA pre-IND guidance and clearance to initiate a second Phase II trial, indicating ongoing clinical development focused on glycemic control and weight management in diabetes[1][9].

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on DM-71.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DM-71.

Explore the full profile